MIS-A related to SARS-CoV-2 infection resembles MIS in children; respiratory symptoms often minimal
Fifty percent of phase 3 clinical trials and 100 percent of vaccine trials at risk for excluding older adults
Cumulative incidence of in-hospital mortality estimated to be 37.4 percent at 90 days
For all donors of convalescent plasma, drop seen in anti-RBD antibody levels from first to last donation